Industry · Health Care · close of 4 Nov 2026
Biotechnology Stocks
9 NSE-listed biotechnology companies, largest first, with each one's stage, price and valuation after the close.
9
companies
4 (44%)
in a Stage 2 uptrend
+1.9%
3-month return, weighted by size
0 · 1 · 4
in Stage 1 · 3 · 4
Filter them in the screener →All Health Care stocks →Industry rotation →
Every biotechnology stock we track
| Stock | Stage | Close | Day | 3 months | From high | RS | P/E | Yield | Market cap |
|---|---|---|---|---|---|---|---|---|---|
| BIOCONBiocon | Stage 4, wk 3 | ₹344.45 | +0.4% | -18.4% | -21.8% | 62 | 101.5 | 0.15% | ₹56,412 Cr |
| ANTHEMAnthem Biosciences | Stage 2, wk 24 | ₹888.30 | +4.0% | +8.4% | -7.3% | 82 | 84.2 | 0.23% | ₹50,058 Cr |
| SAILIFESai Life Sciences | Stage 2, wk 36 | ₹1,546.10 | -0.8% | +13.2% | -7.7% | 93 | 90.2 | — | ₹32,850 Cr |
| ACUTAASAcutaas Chemicals | Stage 2, wk 1 | ₹3,777.30 | -3.2% | +17.2% | -5.7% | 96 | 73.1 | 0.06% | ₹30,925 Cr |
| ONESOURCEOnesource Specialty Pharma | Stage 4, wk 5 | ₹1,583.60 | +0.9% | +3.5% | -15.7% | 52 | — | — | ₹18,160 Cr |
| PANACEABIOPanacea Biotec | Stage 4, wk 5 | ₹344.80 | +3.0% | -17.8% | -43.3% | 41 | — | — | ₹2,107 Cr |
| HESTERBIOHester Biosciences | Stage 3, wk 5 | ₹2,312.00 | +2.2% | -6.8% | -9.2% | 88 | 14.1 | 0.49% | ₹1,967 Cr |
| 3BBLACKBIO3B Blackbio Dx | Stage 2, wk 5 | ₹1,331.50 | -0.2% | +8.1% | -22.2% | 69 | 20.3 | 0.37% | ₹1,143 Cr |
| VIVOBIOTVivo Bio Tech | Stage 4, wk 19 | ₹13.87 | +1.8% | -35.6% | -60.1% | 4 | — | — | ₹31 Cr |
Biotechnology Stocks: quick answers
How many biotechnology stocks are in an uptrend?
As of 4 Nov 2026, 4 of the 9 NSE-listed biotechnology stocks we track are in Stage 2, the uptrend phase, including Anthem Biosciences (ANTHEM), Sai Life Sciences (SAILIFE), Acutaas Chemicals (ACUTAAS) and 3B Blackbio Dx (3BBLACKBIO).
What is the largest biotechnology stock?
Biocon (BIOCON), with a market value of ₹56,412 Cr. It closed at ₹344.45 on 4 Nov 2026, in Stage 4.
Which biotechnology stocks are near their 52-week high?
As of 4 Nov 2026, none of them is within 5% of its 52-week high.